Physician profile

Stephanie Booth

Austin, TX

NPI 1356300990

$1,377.39

in general payments reported to CMS, 2019-2025

6 companies · $142 in 2025

The $142 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$283.58
Education$31.32

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $821.41 2019-2025 Rinvoq
Amgen INC. $183.98 2021-2025 Uplizna, Otezla
Janssen Biotech, INC. $152.05 2020-2025 Tremfya
Aurinia Pharma U.S., INC. $108.07 2023 Lupkynis
Ucb, INC. $86.19 2021-2023 Cimzia
Pfizer INC. $25.69 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephanie Booth

$1,377.39

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $142 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/196861/stephanie-booth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.